NJUPHA PHARMACEUTICAL CO., LIMITED – Trademark Portfolio

Entity Type: 99

NJUPHA PHARMACEUTICAL CO., LIMITED holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include AOCSE, NJUPHA, and ALIMDAES ZINC. The owner is based in HONG KONG.

RM 22, 2/F, FU TAO BUILDING

NO.98, ARGYLE STREET, MONGKOK

HONG KONG 999077 , CN

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

GIPEK
GIPEK
Abandoned 2023
AOCSE
AOCSE
Registered 2022
NJUPHA
NJUPHA
Registered 2021

Trademark Classifications

NJUPHA PHARMACEUTICAL CO., LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does NJUPHA PHARMACEUTICAL CO., LIMITED have?

NJUPHA PHARMACEUTICAL CO., LIMITED has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.

What trademark classes does NJUPHA PHARMACEUTICAL CO., LIMITED file in?

NJUPHA PHARMACEUTICAL CO., LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are NJUPHA PHARMACEUTICAL CO., LIMITED's most well-known trademarks?

NJUPHA PHARMACEUTICAL CO., LIMITED's registered trademark portfolio includes well-known marks such as AOCSE, NJUPHA, and ALIMDAES ZINC. These are among 3 currently registered trademarks in the portfolio.

What is NJUPHA PHARMACEUTICAL CO., LIMITED's trademark registration success rate?

NJUPHA PHARMACEUTICAL CO., LIMITED has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.